PharmaEngine Asset Resilience Ratio
PharmaEngine asset resilience ratio. PharmaEngine (4162) has an Asset Resilience Ratio of 62.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PharmaEngine liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PharmaEngine (2009–2024)
Asset resilience ratio of PharmaEngine from 2009 to 2024. This chart shows how PharmaEngine's Asset Resilience Ratio has changed over time. Read PharmaEngine (4162) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PharmaEngine's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PharmaEngine total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$3.09 Billion | 62.91% |
| Total Liquid Assets | NT$3.09 Billion | 62.91% |
Asset Resilience Insights
- Very High Liquidity: PharmaEngine maintains exceptional liquid asset reserves at 62.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PharmaEngine Industry Peers by Asset Resilience Ratio
Compare PharmaEngine's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
PharmaEngine Asset Resilience Ratio by Year (2009–2024)
PharmaEngine asset resilience ratio by year from 2009 to 2024. The table below shows the annual Asset Resilience Ratio data for PharmaEngine.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.03% | NT$2.87 Billion ≈ $90.33 Million |
NT$5.85 Billion ≈ $184.24 Million |
-20.58pp |
| 2023-12-31 | 69.61% | NT$2.75 Billion ≈ $86.72 Million |
NT$3.95 Billion ≈ $124.57 Million |
+21.90pp |
| 2022-12-31 | 47.71% | NT$1.89 Billion ≈ $59.62 Million |
NT$3.97 Billion ≈ $124.97 Million |
+6.41pp |
| 2021-12-31 | 41.30% | NT$1.66 Billion ≈ $52.39 Million |
NT$4.03 Billion ≈ $126.85 Million |
+4.27pp |
| 2020-12-31 | 37.03% | NT$1.56 Billion ≈ $49.09 Million |
NT$4.21 Billion ≈ $132.54 Million |
-54.17pp |
| 2019-12-31 | 91.20% | NT$3.32 Billion ≈ $104.69 Million |
NT$3.64 Billion ≈ $114.79 Million |
+5.30pp |
| 2018-12-31 | 85.90% | NT$3.30 Billion ≈ $104.11 Million |
NT$3.85 Billion ≈ $121.19 Million |
+20.16pp |
| 2017-12-31 | 65.74% | NT$2.70 Billion ≈ $85.15 Million |
NT$4.11 Billion ≈ $129.52 Million |
+13.52pp |
| 2016-12-31 | 52.23% | NT$2.07 Billion ≈ $65.14 Million |
NT$3.96 Billion ≈ $124.74 Million |
-31.76pp |
| 2015-12-31 | 83.98% | NT$2.72 Billion ≈ $85.69 Million |
NT$3.24 Billion ≈ $102.03 Million |
+79.02pp |
| 2010-12-31 | 4.96% | NT$4.72 Million ≈ $148.86K |
NT$95.27 Million ≈ $3.00 Million |
-50.08pp |
| 2009-12-31 | 55.04% | NT$23.00 Million ≈ $724.63K |
NT$41.79 Million ≈ $1.32 Million |
-- |
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more